Press Releases

10.11.2024

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

10.10.2024

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

10.09.2024

Pfizer Declares Fourth-Quarter 2024 Dividend

10.08.2024

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

09.25.2024

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

09.20.2024

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

09.17.2024

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts

09.14.2024

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

09.14.2024

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

09.11.2024

Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024

08.28.2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

08.27.2024

Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare